EcoR1 Capital, LLC: LAKEFRONT BIOTHERAPEUTICS NV (GLPG): Quarterly 13F Position History
As of Q2 2026, EcoR1 Capital, LLC reported 1,667,119 shares of LAKEFRONT BIOTHERAPEUTICS NV (GLPG), worth $50.0M and representing 2.5% of its 13F equity book. The position first appeared in Q2 2016 and has been disclosed across 41 13F-HR filings in Pactolio's tracked window.
- 1,667,119Shares Held (Latest Filing)
- $50.0MReported Market Value (Latest Filing)
- 2.5%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$33.3KQuarter-over-Quarter Value Change
- 5,756,268Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 41 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,667,119 | 0 | – | $50.0M | 2.5% | $30.0 |
| Q1 2026 | 1,667,119 | 0 | – | $50.0M | 2.1% | $30.0 |
| Q4 2025 | 1,667,119 | 0 | – | $54.5M | 2.5% | $32.7 |
| Q3 2025 | 1,667,119 | +630,174 | +60.8% | $57.7M | 2.8% | $34.6 |
| Q2 2025 | 1,036,945 | +881,939 | +569.0% | $29.0M | 1.7% | $28.0 |
| Q1 2025 | 155,006 | 0 | – | $3.9M | 0.2% | $25.1 |
| Q4 2024 | 155,006 | 0 | – | $4.3M | 0.2% | $27.5 |
| Q3 2024 | 155,006 | 5,601,262 | -97.3% | $4.5M | 0.2% | $28.8 |
| Q2 2024 | 5,756,268 | 0 | – | $142.6M | 4.4% | $24.8 |
| Q1 2024 | 5,756,268 | 0 | – | $185.4M | 4.7% | $32.2 |
| Q4 2023 | 5,756,268 | 0 | – | $234.0M | 6.1% | $40.6 |
| Q3 2023 | 5,756,268 | 0 | – | $198.9M | 6.8% | $34.5 |
| Q2 2023 | 5,756,268 | +1,511,623 | +35.6% | $234.0M | 6.2% | $40.7 |
| Q1 2023 | 4,244,645 | +513,915 | +13.8% | $164.0M | 5.3% | $38.6 |
| Q4 2022 | 3,730,730 | +533,230 | +16.7% | $165.6M | 5.0% | $44.4 |
| Q3 2022 | 3,197,500 | 0 | – | $136.3M | 4.0% | $42.6 |
| Q2 2022 | 3,197,500 | +1,876 | +0.1% | $178.4M | 6.2% | $55.8 |
| Q1 2022 | 3,195,624 | +971,221 | +43.7% | $198.2M | 6.2% | $62.0 |
| Q4 2021 | 2,224,403 | +665,654 | +42.7% | $122.6M | 3.9% | $55.1 |
| Q3 2021 | 1,558,749 | +1,558,749 | – | $82.0M | 2.9% | $52.6 |
| Q2 2021 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2021 | 0 | 46,666 | -100.0% | $0 | 0.0% | – |
| Q4 2020 | 46,666 | +46,666 | – | $4.6M | 0.3% | $99.0 |
| Q3 2020 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2020 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2020 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2019 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2019 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2019 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2019 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2018 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2018 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2018 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2018 | 0 | 110,384 | -100.0% | $0 | 0.0% | – |
| Q4 2017 | 110,384 | 130,392 | -54.2% | $10.3M | 1.4% | $93.8 |
| Q3 2017 | 240,776 | 337,729 | -58.4% | $24.5M | 3.4% | $101.8 |
| Q2 2017 | 578,505 | +27,464 | +5.0% | $44.3M | 10.2% | $76.5 |
| Q1 2017 | 551,041 | 10,300 | -1.8% | $47.5M | 13.1% | $86.2 |
| Q4 2016 | 561,341 | +60,765 | +12.1% | $36.0M | 12.5% | $64.2 |
| Q3 2016 | 500,576 | +61,191 | +13.9% | $32.4M | 12.4% | $64.7 |
| Q2 2016 | 439,385 | – | – | $24.4M | 11.1% | $55.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did EcoR1 Capital, LLC first disclose a GLPG position in 13F-HR filings?
EcoR1 Capital, LLC first reported LAKEFRONT BIOTHERAPEUTICS NV (GLPG) on its 13F-HR filing for the period ending 2016-06-30 (Q2 2016). The position has appeared on 41 reported quarters within Pactolio's tracked window.
What was EcoR1 Capital, LLC's most recent quarter-over-quarter share-count change in GLPG?
EcoR1 Capital, LLC held the same 1,667,119 shares of GLPG between Q1 2026 and Q2 2026, so the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent EcoR1 Capital, LLC's cost basis in GLPG?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.